ArticleLancet regional health. Americas2026

Real-world study of treatment patterns and outcomes in patients with HR+ breast cancer after progression on CDK4/6 inhibitor therapy.

Akshara Singareeka Raghavendra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.